NKTR : Insider Transactions for Nektar Therapeutics | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Nektar Therapeutics (NKTR)

$1.76

0.05 (2.5%) as of 4:30 Fri 5/17

Download

Exchange:

Nasdaq National Market

Security Type:

Common

Shares Out:

179,400,000

Market Cap:

314.85(M)

Last Volume:

1,142,525

Avg Vol:

2,306,261

52 Week Range:

$0.449 - $1.83

Level I Sector:

Health Care

Level II Sector:

Drugs

Level III Sector:

Drug Delivery

Member Indexes:

	NASDAQ BIOTECHNOLOGY		NASDAQ COMPOSITE
	NASDAQ NNM COMPOSITE

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year

Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	92,653	92,653	204,995	510,803
Total Sell Value	$124,554	$124,554	$194,453	$1,231,647
Total People Sold	4	4	7	10
Total Sell Transactions	4	4	13	34
End Date	2024-02-18	2023-11-17	2023-05-19	2022-05-19

Adjust Filter Settings

Records found: 709

Page 18 of 29

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

SVP Pharma Dev & Mfg Ops

• – –

2017-11-07

4

OE

$25.51

$441,323

D/D

17,300

58,233

-

SVP Pharma Dev & Mfg Ops

• – –

2017-11-07

4

OE

$10.69

$184,937

D/D

17,300

75,533

-

Doberstein Stephen K

SVP & Chief Scientific Officer

• – –

2017-11-07

4

AS

$25.78

$1,944,044

D/D

(75,409)

31,102

-

Doberstein Stephen K

SVP & Chief Scientific Officer

• – –

2017-11-07

4

OE

$9.53

$718,648

D/D

75,409

106,511

-

SVP Pharma Dev & Mfg Ops

• – –

2017-11-06

4

AS

$25.07

$128,283

D/D

(5,117)

58,233

-

SVP Pharma Dev & Mfg Ops

• – –

2017-11-06

4

OE

$10.69

$54,701

D/D

5,117

63,350

-

Doberstein Stephen K

SVP & Chief Scientific Officer

• – –

2017-11-06

4

AS

$24.98

$522,432

D/D

(20,914)

31,102

-

Doberstein Stephen K

SVP & Chief Scientific Officer

• – –

2017-11-06

4

OE

$9.53

$199,310

D/D

20,914

52,016

-

President & CEO

• • –

2017-11-01

4

AS

$23.57

$1,964,182

D/D

(83,334)

152,504

-

President & CEO

• • –

2017-11-01

4

OE

$11.34

$945,008

D/D

83,334

235,838

-

President & CEO

• • –

2017-10-09

4

AS

$24.20

$2,016,659

D/D

(83,333)

152,504

-

President & CEO

• • –

2017-10-09

4

OE

$11.34

$944,996

D/D

83,333

235,837

-

Doberstein Stephen K

SVP & Chief Scientific Officer

• – –

2017-10-05

4

AS

$24.97

$1,090,615

D/D

(43,677)

31,102

-

Doberstein Stephen K

SVP & Chief Scientific Officer

• – –

2017-10-05

4

OE

$9.53

$416,242

D/D

43,677

74,779

-

SVP Pharma Dev & Mfg Ops

• – –

2017-10-05

4

AS

$25.00

$189,575

D/D

(7,583)

58,233

-

SVP Pharma Dev & Mfg Ops

• – –

2017-10-05

4

OE

$10.69

$81,062

D/D

7,583

65,816

-

Labrucherie Gil M

SVP & Chief Financial Officer

• – –

2017-10-02

4

AS

$24.45

$2,934,000

D/D

(120,000)

63,414

-

Labrucherie Gil M

SVP & Chief Financial Officer

• – –

2017-10-02

4

OE

$11.34

$1,360,800

D/D

120,000

183,414

-

SVP & Chief Medical Officer

• – –

2017-10-02

4

AS

$24.21

$1,372,804

D/D

(56,704)

41,575

-

SVP & Chief Medical Officer

• – –

2017-10-02

4

OE

$11.04

$626,012

D/D

56,704

98,279

-

SVP & Chief Medical Officer

• – –

2017-09-29

4

AS

$24.04

$1,040,836

D/D

(43,296)

41,575

-

SVP & Chief Medical Officer

• – –

2017-09-29

4

OE

$11.04

$477,988

D/D

43,296

84,871

-

Director

– • –

2017-09-22

4

AS

$21.97

$109,850

D/D

(5,000)

27,450

-

Kuebler Christopher A

Director

– • –

2017-09-22

4

AS

$21.86

$87,440

D/D

(4,000)

40,500

-

Director

– • –

2017-09-21

4

AS

$21.72

$139,008

D/D

(6,400)

274,223

-

709 Records found	Previous 10 11 12 13 14 15 16 17 18 19 Next	Page 18 of 29

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.